Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 14:16:1604071.
doi: 10.3389/fphar.2025.1604071. eCollection 2025.

Pharmacological properties and therapeutic potential of berberine: a comprehensive review

Affiliations
Review

Pharmacological properties and therapeutic potential of berberine: a comprehensive review

Ke-Qin Fan et al. Front Pharmacol. .

Abstract

In recent decades, the pharmacological properties of botanical drugs have been investigated with increasing depth, offering novel insights into their potential for enhancing healthcare. Berberine (BBR) is an alkaloid extracted from the roots, rhizomes and stem tubers of plants such as Coptis chinensis, Phellodendron amurense, Radix berberidis, and several other plants, which is used not only as an anti-inflammatory and antibacterial agent, but also for the treatment of cancer and chronic diseases. BBR has demonstrated remarkable therapeutic efficacy in the management of disorders affecting the nervous, cardiovascular, and endocrine systems, characterized by its high safety profile and minimal adverse effects. Despite the substantial progress made in understanding BBR's pharmacodynamics, its precise mechanisms of action remain incompletely elucidated and warrant further systematic investigation. This study provides an extensive review of the latest pharmacological findings related to berberine and its therapeutic advancements, offering strong evidence for future research and clinical implementation.

Keywords: application prospects; berberine; pharmacodynamics; pharmacological properties; therapeutic potential.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Technological road-map.
FIGURE 2
FIGURE 2
The mechanism of berberine’s action on the Nervous system.
FIGURE 3
FIGURE 3
The mechanism of berberine’s action on the Cardiovascular system.
FIGURE 4
FIGURE 4
The mechanism of berberine’s action on the Endocrine system.
FIGURE 5
FIGURE 5
The mechanism of berberine’s action on the Digestive system.
FIGURE 6
FIGURE 6
The mechanism of berberine’s action on the Reproductive system.
FIGURE 7
FIGURE 7
The mechanism of berberine’s action on cancer.
FIGURE 8
FIGURE 8
The antibacterial mechanism of berberine.

Similar articles

  • Prescription of Controlled Substances: Benefits and Risks.
    Preuss CV, Kalava A, King KC. Preuss CV, et al. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
  • Inhibitory effects of berberine against Streptococcus mutans: an in vitro insight on its anticaries potential.
    Zeng C, Jiang W, Liu C, Yu R, Li Y, Li P, Cao Y. Zeng C, et al. Microbiol Spectr. 2025 Sep 2;13(9):e0070025. doi: 10.1128/spectrum.00700-25. Epub 2025 Aug 12. Microbiol Spectr. 2025. PMID: 40792499 Free PMC article.
  • Management of urinary stones by experts in stone disease (ESD 2025).
    Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, Elhowairis M, Galán-Llopis JA, Geavlete P, Guimerà Garcia J, Isern B, Jinga V, Lopez JM, Mainez JA, Mitsogiannis I, Mora Christian J, Moussa M, Multescu R, Oguz Acar Y, Petkova K, Piñero A, Popov E, Ramos Cebrian M, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A. Papatsoris A, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
  • Systemic Inflammatory Response Syndrome.
    Baddam S, Burns B. Baddam S, et al. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613449 Free Books & Documents.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.

References

    1. Abudureyimu M., Yu W., Cao R. Y., Zhang Y., Liu H., Zheng H. (2020). Berberine promotes cardiac function by upregulating PINK1/Parkin-Mediated mitophagy in heart failure. Front. Physiol. 11, 565751. 10.3389/fphys.2020.565751 - DOI - PMC - PubMed
    1. Adnan M., Rasul A., Hussain G., Shah M. A., Sarfraz I., Nageen B., et al. (2021). Physcion and physcion 8-O-β-D-glucopyranoside: natural anthraquinones with potential anticancer activities. Curr. Drug Targets 22 (5), 488–504. 10.2174/1389450121999201013154542 - DOI - PubMed
    1. Akula S. M., Ruvolo P. P., McCubrey J. A. (2020). TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer. Aging (Albany NY) 12 (3), 2777–2797. 10.18632/aging.102776 - DOI - PMC - PubMed
    1. Alruhaimi R. S., Siddiq A. M., Ahmeda A. F., Bin-Ammar A., Kamel E. M., Hassanein E. H. M., et al. (2024). Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E-NTPDase in acute hyperlipidemia. Drug Dev. Res. 85 (2), e22166. 10.1002/ddr.22166 - DOI - PubMed
    1. Amssayef A., Eddouks M. (2023a). Alkaloids as vasodilator agents: a review. Curr. Pharm. Des. 29 (24), 1886–1895. 10.2174/1381612829666230809094313 - DOI - PubMed

LinkOut - more resources